Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Using HPI and AFM to prevent low blood pressure during general anesthesia

Official title: The Use of the Hypotension Prediction Index (HPI) Combined With the Assisted Fluid Management (AFM) Software for Perioperative Hemodynamic Optimization in Patients Undergoing General Anesthesia.

Run by National and Kapodistrian University of Athens · NCT07301307 · Data updated 2026-11-12

This trial will test whether the Hypotension Prediction Index together with Assisted Fluid Management can reduce how often and how long adults experience low blood pressure during surgery under general anesthesia.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment100 (estimated)
SponsorNational and Kapodistrian University of Athens
Academic / other
Locations1 site (Athens, Attica)
StatusRecruiting
StartedMarch 15, 2026
Main results expectedOctober 2026
Study endsMarch 2027
Registry record updatedApril 20, 2026
Trial IDNCT07301307 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults having elective surgery under general anesthesia with planned invasive arterial pressure monitoring for at least two hours, a target MAP ≥65 mmHg, and ASA physical status ≤4 are ideal candidates.

Probably not a fit

Patients having emergency surgery, those with a target MAP other than 65 mmHg, severe preoperative hypotension, or severe heart failure (e.g., LVEF <20%) are unlikely to benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, randomized trial enrolling 100 adults undergoing elective surgery with invasive arterial monitoring to compare goal-directed hemodynamic therapy guided by HPI and AFM versus conventional management. The HPI software predicts impending hypotension from the arterial waveform, giving clinicians early warning, while the AFM algorithm advises crystalloid administration only when it is expected to raise stroke volume. Primary outcomes include incidence and duration of intraoperative hypotension, with secondary outcomes addressing fluid and vasopressor use and perioperative organ-related complications. Participants must have general anesthesia expected to last at least two hours and a target MAP of ≥65 mmHg.

Why it matters

Potential benefit: If successful, this approach could reduce intraoperative hypotension and related postoperative organ complications by enabling earlier, more targeted fluid and vasopressor therapy.

How similar studies have gone: Prior studies of HPI and of goal-directed hemodynamic therapy have reported reductions in hypotension and improved hemodynamic targets, but evidence specifically combining HPI with AFM guidance is still limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age \> 18 years
* Intraoperative monitoring \> 2 hours or general anesthesia \> 2 hours
* Invasive arterial pressure monitoring
* Target MAP ≥ 65 mm Hg intraoperatively
* Written informed consent preoperatively
* ASA Physical Status ≤ 4

Exclusion Criteria:

* Target MAP other than 65 mm Hg
* Severe preoperative hypotension (MAP \< 65 mm Hg)
* Severe heart failure (e.g. LVEF \< 20%)
* Emergency surgery

Where it's running

  • 2nd University Department of Anesthesiology, Attikon University Hospital
    Athens, Attica, Greece
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.